TL;DR: Even a globally reputable company using trusted partners can stumble into serious compliance breaches online. All pharma professionals should be proactive, transparent, and vigilant—especially with third-party digital campaigns. The future of ethical pharmaceutical advertising depends on it. For many in pharma, the digital landscape can feel like quicksand—seemingly solid

What 214 Social Media cases taught me about compliance risk I’ve just finished reviewing 214 PMCPA cases where social media played a role. The pattern is undeniable: LinkedIn and other platforms are now a leading source of ABPI Code breaches. And the worrying part? Most of these breaches started with

Ever wondered how something as innocent as a LinkedIn ‘like’ could pull an entire pharma company into PMCPA hot water? I once underestimated how quickly a digital echo can travel, but the Moderna mRESVIA PMCPA case showed the true power (and risk) of our online footprint. Let’s break down what

Let me take you behind the scenes of a Jazz Pharmaceuticals case that could have happened to any of us. In my early years as a final signatory I found myself agonising over whether mentioning a drug’s brand name too many times in a Press Release could result in a

Every congress season, the influx of last-minute speaker decks exposes a familiar vulnerability in pharmaceutical communications. Speed, while necessary, brings competitor risk sharply into focus. Substantiation lapses, inconsistencies, and unsupported claims can inadvertently invite challenge under the 2024 ABPI Code Clauses 6 and 14. In this article, I outline where

Every spring and summer, the congress season breathes energy into the pharmaceutical world—a moment brimming with anticipation for product progress, emerging data, and unbiased scientific interchange. Yet at every congress, a quiet tension surfaces: how do industry professionals champion transparency about pipeline assets without veering into the territory of promotion?

A brand manager surprised me when she asked me if the new ad was ‘balanced’. I think she said it with the hope that I’d just nod and move on. Instead, I had to pause — because in pharma, ‘balance’ isn’t a box-tick, it’s a fundamental that makes or breaks

TL;DR: If your sponsorship declaration isn’t crystal-clear, up-front, and brutally honest about influence? It’s non-compliant. Tidy up your wording, lock in placement, and test with ruthless checks. We have all been there – a careful ‘Supported by’ tagline—halfway down a very long web page, lost in other branding, or buried

I have seen the supposedly innocent disease-awareness flyers! If you think ‘non-promotional’ means ‘risk-free,’ you’re in for a surprise – and so was the team that found themselves knee-deep in Code breach chaos. Let me take you through what most people get wrong about the ABPI Code, and why even